Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04126369

Impact of Mindfulness Intervention on Quality of Life in Patients With Drug-resistant Epilepsy.

This study evaluates a mindfulness intervention in patients with drug resistant epilepsy.

Half of participants will follow a mindfulness programme, while the other half will follow a self management programme.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Drug Resistant Epilepsy Brain Diseases Central Nervous System Diseases Epilepsy Nervous System Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Epileptology Department of The Grenoble University Hospital, Grenoble, France

Loading trial locations.

About this study

Drug-resistant epilepsy is associated with an alteration of the quality of life mainly related to psychiatric comorbidities (anxiety and depression). The management of these comorbidities is therefore essential in patients with drug resistant epilepsy, Ideally through non-drug management to minimize the side effects of molecules.

The goal of mindfulness interventions in pathology is to learn to better live with a chronic disease by reducing the stress resulting from the disease, by increasing benevolence towards oneself, the acceptance of the disease and reducing the ruminations linked with the pathology.

Mindfulness therefore seems to be a good way for these patients to improve the management of their emotions and thus improve their quality of life what the investigators propose to evaluate in this study.

The study consists of two phases

  • First phase: comparative randomized study (primary endpoint):
  • After inclusion, a 2 months baseline follow-up is carry to collect the judgement criteria without intervention.
  • At the end of this period, patients will be randomly assigned to the mindfulness intervention group or the control group with the psycho educative programme. Both programmes will takes 3 months.
  • Then a 6-months post-intervention follow-up period for both groups

Patients will have assessment visits every 3 months. They will also complete a daily notebook including the number of seizures they have done and a scale of their "interior weather".

  • Second phase (optional):

At the end of the first phase, patients in the control group will be able to benefit from the mindfulness programme and will be followed at the end of the programme for 6 months.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Drug resistant epilepsy according to the criteria of the International League Against Epilepsy (ILAE)
  • Stable therapy for at least 3 months
  • No planned surgery
  • Patient affiliated to social security insurance or beneficiary of social security insurance.
  • Signed consent

Exclusion criteria

  • Patient who has previously had or regularly practicing mindfulness
  • Patient with psychogenic non-epileptic seizures
  • Pregnant woman, breastfeeding mother, person deprived of liberty by judicial or administrative decision, person subject to legal protection
  • Patient with relationship disorders related to psychosis
  • Patients who are unable or unwilling to work as a group or person unable to understand the topics discussed during session.

Treatment and study plan

Mindfulness intervention

Other

The mindfulness program is conducted in a group session of up to 10 people. Each session lasts 2 hours. A total of 12 sessions will be conducted by a practitioner who is specifically trained in this type of programme.

psycho educative programme

Other

The psycho-educational control intervention will follow the same format and structure as the mindfulness meditation intervention in terms of group format, session duration and frequency. This is a therapeutic education programme developed for several years in the neurology department of the university hospital of Lyon and Grenoble. The program follows the repository recommended by the french league against epilepsy.

Primary outcomes

  1. Evolution of Quality Of Life In Epilepsy-Problems questionnaire (QOLIE31-P) score.

    Time frame: 9 months

    The QOLIE31-P questionnaire has been developed specifically to measure the quality of life of patients with epilepsy. The score ranges from 0 to 100 points. Higher scores reflect better quality of life; lower ones, worse quality of life.

    The score of QOLIE31-P will be assess prior to intervention and then at month 3, month 6 and month 9 after the beginning of the intervention.

    Ref : Cramer JA. Van Hammee G. N132 Study Group. Maintenance of improvement in health-related quality of life during long-term treatment with levetiracetam. Epilepsy & Behavior 2003; 4:118-123.

Secondary outcomes

  1. Evolution of seizures frequency

    Time frame: 9 months

    The number of seizures will be plot by the patient on a daily notebook throughout the study period.

  2. Evolution of psychiatric morbidity

    Time frame: 9 months

    The evolution of psychiatric morbidity will be assess with the Neurological Disorders Depression Inventory for Epilepsy (NNDI-E) questionnaire The NNDIE questionnaires will be assess prior to intervention month 0 and then at month 3, month 6 and month 9 after the beginning of the intervention.

    Ref: Gilliam et al., The Lancet Neurology, 2006 Micoulaud-Franchi et al., Epilepsy and Behavior, 2015

  3. Evolution of anxiety level

    Time frame: 9 months

    The evolution of anxiety level will be assess with the State Trait Anxiety Inventory (STAI) questionnaire.

    The STAI questionnaire will be assess prior to intervention month 0 and then at month 3, month 6 and month 9 after the beginning of the intervention.

    Ref : Spielberger CD, 1983. Traduction française Schweitzer MB et Paulhan I, 1990. D'après Guelfi JD (58).

  4. Evolution of stress management

    Time frame: 9 months

    The evolution of stress management will be assess with the Emotion Regulation abilities Questionnaire (ERQ).

    The ERQ questionnaire will be assess prior to intervention month 0 and then at month 3, month 6 and month 9 after the beginning of the intervention.

  5. Evolution of stress level

    Time frame: 9 months

    The evolution of stress will be assess with the level of cortisol salivary. The salivary cortisol level will be assess prior to intervention month 0 and then at month 3, month 6 and month 9 after the beginning of the intervention.

  6. Evolution of self acceptance and interoception

    Time frame: 9 months

    The evolution of self acceptance and interoception will be assess with the Self-Compassion Scale - Short Form (SCS-SF) questionnaire.

    The SCS-SF questionnaires will be assess prior to intervention month 0 and then at month 3, month 6 and month 9 after the beginning of the intervention.

    Ref: Raes, F., Pommier, E., Neff, K. D., & Van Gucht, D. (2011). Construction and factorial validation of a short form of the Self-Compassion Scale. Clinical Psychology & Psychotherapy. 18, 250-255.

  7. Evolution of self acceptance and interoception

    Time frame: 9 months

    The evolution of self acceptance and interoception will be assess with the Multidimensional Assessment of Interoceptive Awareness (MAIA) questionnaire.

    The MAIA questionnaires will be assess prior to intervention month 0 and then at month 3, month 6 and month 9 after the beginning of the intervention.

    Ref: Mehling WE, Price C, Daubenmier JJ, Acree M, Bartmess E, Stewart A (2012) The Multidimensional Assessment of Interoceptive Awareness (MAIA). PLoS ONE 7(11)

  8. Evolution of self acceptance and interoception

    Time frame: 9 months

    The evolution of self acceptance and interoception will be assess with the Five Facet Mindfulness Questionnaire (FFMQ) The FFMQ questionnaires will be assess prior to intervention month 0 and then at month 3, month 6 and month 9 after the beginning of the intervention.

    Ref: Baer, R.A., Carmody, J., & Hunsinger, M (2012) FFMQ-SF. Journal of Clinical Psychology 7: 755-765 (2012)

  9. Evolution of cognitive functions

    Time frame: 9 months

    The evolution of cognitive functions will be assess with the Cambridge Neuropsychological Test Automated Battery (CANTAB).

    The CANTAB cognitive tests will be assess prior to intervention and then at month 3 and month 9 after the beginning of the intervention.

Study contacts

Contact information is provided by the study sponsor or research team.

Cécile SABOURDY, MD

CONTACT

[email protected]

04767656.9 ext. +33

Sponsors and collaborators

Lead sponsor

University Hospital, Grenoble

Other

Registry information

Acronym: EPIMEDIT

Important dates

Study start
2020
Primary completion
2026
Study completion
2027
First posted
Oct 15, 2019
Registry last updated
May 8, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.